
A chemist who spent years trying to make fuel from plants found a more useful reversal: make protein from methane. Alan Shaw’s second biotech act is a lesson in recognizing the market hiding inside the science.
Calysta is a San Mateo, California biotechnology company that uses a patented gas-fermentation platform to turn methane into FeedKind, a single-cell protein for aquaculture, livestock and pet feed - and increasingly human food. Its bacteria eat natural gas instead of arable land, plants or animals, producing protein with a low environmental footprint. Backed by Cargill, BP and Temasek and partnered with Adisseo through the Calysseo joint venture, Calysta opened the world's first industrial-scale single-cell protein plant in Chongqing, China in 2022.
Triplebar is an Emeryville, California biotech company that pairs a high-throughput microfluidic screening platform with AI genomic models to run evolution at hyper-speed. By packing tens of millions of picoliter microreactors onto a palm-sized chip and testing thousands per second, it generates matched genotype-phenotype datasets that let partners optimize cell lines and microbial strains far faster and cheaper than conventional lab work. The platform powers products across food (precision fermentation, cultivated meat) and biopharma (biologics, cell-engaging cancer therapies).